“Exceptional” Long-term Data for Bimekizumab in PsO
Psoriasis patients treated with bimekizumab (Bimzelx, UCB) quickly achieved and maintained high clinical and health-related quality-of-life response rates through four years. Study author Mark G. Lebwohl, MD, the Dean for Clinical Therapeutics at the Icahn School of Medicine at Mount Sinai and Professor and Chairman Emeritus of the Kimberly and Eric J. Waldman Department of […]